Search Results - therapeutic

34 Results

Sort By:

The androgen receptor regulates a druggable translational regulon in advanced prostate cancer

Therapeutic targets to treat Androgen Receptor Deficient and Low Prostate Cancers Methods to treat Androgen Receptor Deficient and Low Prostate Cancers by targeting 4EBP1 Prostate cancer is the second most common male cancer, affecting cells of the prostate glands. About 90% of these early stage prostate cancers are dependent on androgens for...

Published: 8/28/2024 | Updated: 8/28/2024 | Inventor(s): Andrew Hsieh

Keywords(s): Target

Category(s): Therapeutic

TARGETING PRAC1 IN CASTRATION RESISTANT PROSTATE CANCER

Therapeutic peptide and biomarkers for castration-resistant prostate cancer (CRPC) Synthetic peptide targeting PRAC1 has been developed for the treatment of CRPC. Prostate cancer is an androgen dependent tumor, and the androgen receptor (AR) drives numerous mechanisms involved in disease progression. The standard therapy for metastatic...

Published: 5/15/2025 | Updated: 7/5/2024 | Inventor(s): Michael Haffner, Jin-Yih Low, Elizabeth Wasmuth, Chitvan Mittal

Keywords(s): Biomarker, Protein / Peptide, Target

Category(s): Diagnostic, Therapeutic

NKG2D-SCD-T-Engager

Therapeutics targeting NKG2D ligands for elimination of cancer cells and senescent cells A novel fusion protein targeting NKG2D ligands for eradicating cancer and senescent cells. Natural killer group 2 member D ligands (NKG2DLs) are consistently upregulated in cancer cells, senescent cells, and cells undergoing genotoxic stress. Moreover,...

Published: 5/15/2025 | Updated: 3/10/2024 | Inventor(s): Thomas Schmitt, Roland Strong

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Method of adoptive T cell therapy utilizing notch signaling to enhance efficacy

Notch Activation to Improve Persistence and Efficacy of T Cell Therapies Method of using Notch ligands during culturing to improve the persistence and efficacy of CAR T cell therapies. While CAR T-based cell therapies are promising, the persistence, proliferation, and efficacy of those engineered T cell therapies need to be improved. Additionally,...

Published: 10/14/2024 | Updated: 3/10/2024 | Inventor(s): Irwin Bernstein, Stanley Riddell, Margot Pont

Keywords(s): Immuno Oncology, Target

Category(s): Therapeutic

Engineering B cells to obtain CD40 signals from antigen instead of CD40Ligand (CD40L)

Designing universal donor B cells that will respond to antigen independently of T cell boost Methods to link CD40 signaling to antigen binding independently of CD40L binding in order to potentiate B-cell responses. Vaccines increase immunity against infections by stimulating B cells to produce antibodies against the infectious agent. In addition...

Published: 12/6/2023 | Updated: 12/6/2023 | Inventor(s): Justin Taylor, Laila Shehata, Marti Tooley

Keywords(s): HSC Therapy, Hybridoma / Antibody, Immuno Oncology

Category(s): Therapeutic

MHC class II restricted T cell receptors targeting mutations in EGFR

MHC class II restricted T cell receptors targeting mutations in EGFR Compositions and methods for targeting EGFR antigens (for e.g., to treat or manage cancer) Activating mutations in EGFR cause a subset of non-small cell lung cancer that occurs preferentially in women and non-smokers. EGFR mutated lung cancer responds to small molecule kinase...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy, Therapeutic

Development of Fully Human Anti-Human Siglec-8 Antibodies as Basis for Therapeutics to Treat Eosinophilic and Mast Cell Disorders

Novel biologics targeting Siglec-8 to treat eosinophil-driven diseases Fully human mAbs, bispecific antibodies, and NK CARs that target Siglec-8. Siglec-8 is a transmembrane protein expressed on mature eosinophils, mast cells, and (to a lesser degree) basophils. Excessive eosinophil and mast cell activity have been implicated in the pathology...

Published: 2/12/2025 | Updated: 7/18/2023 | Inventor(s): Roland Walter, George Laszlo

Keywords(s): Hybridoma / Antibody, Immuno Oncology, Target

Category(s): Therapeutic

Therapeutic targeting PRAME with mTCRCAR T cells 1 in Acute Myeloid Leukemia

TCR mimic CAR T cells targeting PRAME/HLA-A2 Chimeric antigen receptor (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALYVDSLFFL (ALY) / HLA-A*0201 (HLA-A2) to treat PRAME-expressing cancers. PRAME is aberrantly expressed in childhood and adult AML and is absent in normal hematopoietic cells, providing an ideal target for...

Published: 10/14/2024 | Updated: 2/28/2023 | Inventor(s): Soheil Meshinchi, Danielle Kirkey, Anisha Loeb, Quy Le

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Candidate T cell epitopes of short H2A histone variants (novel cancer testis antigens)

Novel Cancer/Testis Antigen: T Cell Epitopes of Short H2A Histone Variants Short H2A histone variant epitopes commonly expressed in Diffuse Large B Cell Lymphoma to be used as immunotherapy targets By analyzing data from patients with a variety of cancers, Dr. Jay Sarthy’s group at Fred Hutch Cancer Center have identified short H2A histone...

Published: 2/4/2025 | Updated: 1/25/2023 | Inventor(s): Jay Sarthy, Antoine Molaro, Marie Bleakley, Guo-Liang Chew

Keywords(s): Target

Category(s): Therapeutic

High Affinity MAGE-A1 T-cell Receptors

TCR Cell Therapy Targeting MAGE-A1 High-affinity MAGE-A1-specific TCR for the treatment of multiple myeloma and solid tumors. The MAGE family are CTAs expressed in many tumor types and MAGE-A1 has been shown to directly drive tumorigenesis. Specifically, MAGE-A1 is expressed in about 50% of multiple myeloma, up to 60% in triple negative...

Published: 5/15/2025 | Updated: 1/19/2023 | Inventor(s): Aude Chapuis, Thomas Schmitt, Megan McAfee

Keywords(s): Immuno Oncology, Target

Category(s): Cell Therapy, Therapeutic

1 2 3 4